| Literature DB >> 31266165 |
Alexander Brezhnev1, Prasanna Neelakantan2, Ray Tanaka3, Sergey Brezhnev4, George Fokas5, Jukka P Matinlinna1.
Abstract
Dental materials used in root canal treatment have undergone substantial improvements over the past decade. However, one area that still remains to be addressed is the ability of root canal fillings to effectively entomb, kill bacteria, and prevent the formation of a biofilm, all of which will prevent reinfection of the root canal system. Thus far, no published review has analysed the literature on antimicrobial additives to root canal sealers and their influence on physicochemical properties. The aim of this paper was to systematically review the current literature on antimicrobial additives in root canal sealers, their anti-fouling effects, and influence on physicochemical properties. A systematic search was performed in two databases (PubMed and Scopus) to identify studies that investigated the effect of antimicrobial additives in epoxy resin-based root canal sealers. The nature of additives, their antimicrobial effects, methods of antimicrobial testing are critically discussed. The effects on sealer properties have also been reviewed. A total of 31 research papers were reviewed in this work. A variety of antimicrobial agents have been evaluated as additives to epoxy resin-based sealers, including quaternary ammonium compounds, chlorhexidine, calcium hydroxide, iodoform, natural extracts, antibiotics, antifungal drugs, and antimicrobial agent-functionalised nanoparticles. Antimicrobial additives generally improved the antimicrobial effect of epoxy resin-based sealers mainly without deteriorating the physicochemical properties, which mostly remained in accordance with ISO and ANSI/ADA specifications.Entities:
Keywords: antimicrobial; biofilm; endodontics; epoxy resin; nanoparticle; obturation; quaternary ammonium; root canal; sealer
Year: 2019 PMID: 31266165 PMCID: PMC6784478 DOI: 10.3390/dj7030072
Source DB: PubMed Journal: Dent J (Basel) ISSN: 2304-6767
Search strategy with the keywords used in the PubMed database.
| Search Builder | Search Words | Results |
|---|---|---|
| #1 | “epoxy resin” OR epoxy-based OR amine-epoxy OR amine epoxy OR epoxy OR epoxide | 41,898 |
| #2 | Sealer * OR sealing OR sealant * OR filling * OR cement * | 150,150 |
| #3 | antibacterial OR antimicrobial OR antibiofilm OR anti-biofilm OR biofilm * OR fungus OR fungi OR fungal OR antifungal OR anti-fungal OR bactericidal OR infection OR antiinfective OR anti-infective OR microbial OR bacterial OR nanoparticle * OR antibiotic * | 4,663,057 |
| #1 AND #2 AND #3 | 656 | |
* Asterisk in Pubmed after a search word leads to finding of all terms that begin with a given string of text.
Search strategy with the keywords used in Scopus database.
| Advanced Search Field in Scopus with Key Words | Results |
|---|---|
| (TITLE-ABS-KEY (“epoxy resin” OR epoxy-based OR amine-epoxy OR “amine epoxy” OR epoxy OR epoxide ) AND TITLE-ABS-KEY (sealer * OR sealing OR sealant * OR filling * OR cement *) AND TITLE-ABS-KEY (antibacterial OR antimicrobial OR antibiofilm OR anti-biofilm OR biofilm * OR fungus OR fungi OR fungal OR antifungal OR anti-fungal OR bactericidal OR infection OR antiinfective OR anti-infective OR microbial OR bacterial OR nanoparticle * OR antibiotic *)) | 335 |
* TITLE-ABS-KEY stands for the “Article title, Abstract, Keywords” field in Scopus.
Figure 1PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) flowchart showing the search process.
Figure 2Classification of Antibacterial Compounds Discussed in the Review. Key: QACs = quaternary ammonium compounds; CTR = cetrimide; BAC = benzalkonium chloride; CPC = cetylpyridinium chloride; Biosafe® HM4100™ = 3-(trihydroxysilyl)-propyldimethyloctadecyl ammonium chloride; DMAHDM = dimethylaminododecyl methacrylate; CHX = chlorhexidine digluconate; QPEI = quaternary ammonium polyethylenimine; QAES = quaternary ammonium epoxy silicate; TAP/TAM = triple antibiotic paste/mixture consisting of (minocycline or doxycycline) + metronidazole + ciprofloxacin.
General characteristics of studies included in this review.
| Publication | Epoxy Resin Sealer Tested | Antimicrobial Additive(s) | Methods of Studying the Antimicrobial Activity | Physicochemical Properties Tested | Main Results |
|---|---|---|---|---|---|
| Bailon-Sanchez et al. [ | AH Plus™ | Chlorhexidine digluconate (CHX) liquid 1%, 2% and cetrimide (CTR) 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, and a mixture of both | DCT; Biofilm test: Calgary Biofilm Device (MBEC-high throughput [HTP]; Innovotech, Edmonton, AB, Canada). | Not tested |
AH Plus™ with 1% or 2% CHX: higher antibacterial effect than AH Plus™ alone. Inhibition of Eradication concentrations: 0.3%, 0.4%, 0.5% CTR + 2% CHX. CHX alone: no eradication of biofilm. |
| Ruiz-Linares et al. [ | AH Plus™ | Chlorhexidine digluconate (CHX) liquid 1%, 2% and cetrimide (CTR) 0.1%, 0.2%, 0.3%, 0.5%, and mixture of both | Not tested | Setting time, flow, solubility, radiopacity |
All concentrations: results are within ANSI/ADA Specification No. 57. Setting time: CTR—increased; CHX alone or CHX+CTR decreased. Flow: CTR—reduced; CHX—increased; CHX + CTR = AH Plus alone. |
| Solomonov et al. [ | BJM Root Canal Sealer™, AH Plus™, MM-Seal™ | Biosafe® HM4100™ (3-(Trihydroxysilyl) propyldimethyl-octadecyl ammonium chloride) as an additive into BJM Root Canal Sealer™. | Not tested | Flow, working time, solubility, dimensional change |
Flow: all values within ISO 6876/2012. Dimensional change: all values inconsistent with the ISO 6876/2001. Solubility: AH Plus™ and BJM Root Canal Sealer™ in accordance with ISO 6876/2012. |
| Becker et al. [ | BJM Root Canal Sealer™ | Biosafe® HM4100™ (3-(Trihydroxysilyl) propyldimethyl-octadecyl ammonium chloride) at 0%, 0.4%, 0.8%, 1.6%, 3.3% w/v | Crystal violet staining, Optical density (spectrophotometer). Fluorescence microscopy | Not tested |
Significant reduction in de-novo biofilm formation of 25% and 72% in 1.6% and 3.3% Biofilm viability: significant reduction of 20% and 36% in 1.6% and 3.3% |
| Gjorgievska et al. [ | AH Plus™ | Benzalkonium Chloride (BAC), Cetylpyridinium Chloride (CPC) at 2% w/w | Not tested | Release of BAC and CPC after week 1 and week 4. Compressive strength. |
BAC and CPC release: at week 4 higher than at week 1. CPC release: higher than BAC release at week 1 and 4. Compressive strength: CPC increased; BAC decreased. |
| Gjorgievska et al. [ | AH Plus™ | Benzalkonium Chloride (BAC), Cetylpyridinium Chloride (CPC) at 2% w/w | ADT | Not tested |
AH Plus™ + 2% BAC or 2% CPC: zones of inhibition larger than in pure AH Plus™ ( Pure AH Plus™: no inhibition zones ( |
| Arias-Moliz et al. [ | AH Plus™ | Benzalkonium chloride (BAC) at 1%, 2%, and 3% w/w | DCT; Antibiofilm test: MBEC-high-throughput (HTP) device; CLSM | Setting time, flow, solubility, microhardness, contact angle measurement |
Strength: CPC increased; BAC decreased. Flow: within ISO 6876:2012, but decreased gradually from pure AH Plus™ to AH Plus™ + 1%, 2%, 3% BAC. Solubility: not different in all groups. Contact angle of AH Plus™ + 2% and + 3% BAC: lower than of pure AH Plus™ or with 1% BAC. Better wettability, more hydrophilic surface. Microhardness: AH Plus™ + 3% BAC decreased by 75%; + 2% BAC decreased by 50%, compared with pure AH Plus™. |
| Seung et al. [ | AH Plus™ | Dimethylaminododecyl methacrylate (DMAHDM) at 2.5%, 5%, 10% w/w; Nanosilver (NAg) 0.05%, 0.10%, 0.15% w/w; Combination of DMAHDM 2.5% w/w and NAg 0.15% w/w | DCT (modified DCT) | Setting time, flow, solubility, dimensional change. |
All the tested properties of AH Plus™ with 2.5% DMAHDM and 0.15% NAg did not change significantly. Only 10% DMAHDM caused physical properties to go beyond ANSI/ADA Specification No. 57. The mean CFU/mL for AH Plus™ + 2.5% DMAHDM and AH Plus™ with 2.5% DMAHDM and 0.15% NAg were significantly lower compared with the control at each time point (day 1, day 7, day 14). AH Plus™ with 0.15% NAg had a significant bacterial reduction on day 1 compared with pure AH Plus™, but no difference at days 7 and 14. |
| Shih et al. [ | AH Plus™ | Hinokitiol at 0.2%, 0.5%, 1%, and 2% w/w 0.2% used for physical, biological and antimicrobial tests | ADT; | Setting time, working time, flowability, film thickness, solubility, cytotoxicity. |
ADT: pure AH Plus™-clear inhibition zones [methicillin-resistant Physicochemical properties: AH Plus™ + 0.2% hinokitiol—within ISO. |
| Saha et al. [ | AH Plus™ | Herbal extracts: | ADT | Not tested |
AH Plus™ with Licorice showed the highest inhibition zones. Licorice: the highest inhibition zones were against |
| Kuga et al. [ | Sealer 26™ | Iodoform at 0.275 g: 2.1 g; 0.55 g: 2.1 g; 1.1 g: 2.1 g (to the sealer) | Not tested | Setting time, flow, solubility, pH, calcium release. |
Setting time: deteriorated significantly; Flow: not significant differences, all > 20 mm; Solubility (mass loss): pure AH Plus™ −2%; modified groups −9.38% to −10.98%. pH: only at 24 h significant differences—1.1 g and 0.55 g < 0.275 g and pure Sealer 26™ other groups (7 days, 14 days, 21 days, 28 days, 45 days): not significant differences; Calcium release: not significant differences; |
| Duarte et al. [ | AH Plus™ | Calcium hydroxide (CH) at 5% w/w and 10% w/w | Not tested | pH, calcium release (Ca2+) |
pH: pure AH Plus™ < AH Plus™ 5% CH < AH Plus™ 10% CH at 24 h, 48 h, 7 days; pH: pure AH Plus™ < AH Plus™ 5% CH = AH Plus™ 10% CH at 14, 30 days; Ca2+ release: pure AH Plus™ < AH Plus™ 5% CH < AH Plus™ 10% CH at 24 h, 48 h, 7 days, 14 days, 30 days |
| Duarte et al. [ | AH Plus™ | Calcium hydroxide (CH) at 5% w/w and 10% w/w | Not tested | Setting time, flow, film thickness, solubility, dimensional changes, radiopacity |
Setting time: not significant differences; Flow: pure AH Plus™ = AH Plus™ 5% CH; AH Plus™ 10% CH significantly lower; all > 20 mm. Film thickness: pure AH Plus < AH Plus™ 10% CH = AH Plus™ 5% CH; Solubility: pure AH Plus™ < AH Plus™ 10% CH; pure AH Plus™ = AH Plus™ 10% CH; AH Plus 5% CH = AH Plus™ 10% CH; Dimensional changes: not significant differences (expansion ranges 0.57 ± 0.1% to 1.14 ± 0.26%); Radiopacity: not significant differences, all groups > 3 mm Al. |
| Andolfatto et al. [ | AH Plus™ | Amoxicillin added at 0.25% w/w, 0.5%, 1%, 2.5%, 5.5%, 7.5%, 10% w/w into the sealer | CFU counts | Flow, setting time, cytocompatibility |
1% amoxicillin: no increase in antibiofilm activity. >1% amoxicillin: physicochemical properties deteriorated. Flow: 0.25%, 0.5% and 1% within the ISO. Setting time: decreased at 0.25% and higher. Cytocompatibility: viability of fibroblasts—not diminished; changes in the cytoskeleton—not affected. |
| Kangarlou et al. [ | AH Plus™, AH 26™ | Amoxicillin; triple antibiotic paste (TAP); nanosilveradded at 10% w/w into sealers. | ADT | Not tested |
Amoxicillin and TAP: improved antibacterial properties. The effect decreased with time. Incorporation of nanosilver did not improve the antibacterial effect. |
| Vanapatla et al. [ | AH Plus™ | Triple antibiotic mixture (TAM) added at 10% w/w together with a gutta-percha point | CFU counts | Not tested |
Antibacterial effect increased significantly (increased percentage reduction in the CFU of |
| Razmi et al. [ | AH 26™ | Amoxicillin; doxycycline added at 1%, 5%, 10%, 25%, 50% w/w into the sealer | ADT; CFU counts (In vitro human root inoculation method) | Not tested |
AH 26™ pure and + 1%, 5%, 10%, 25% and 50% of amoxicillin or doxycycline: zones of inhibition; pure AH 26™: smaller zones. The peak of antimicrobial activity: at 1%. AH 26™ + amoxicillin: larger inhibition zones than AH 26™ + doxycycline in all concentrations. The mean log10CFU for AH 26™ doxycycline combination: lower. AH 26™ + amoxicillin and AH 26™ + doxycycline: total eradication of |
| Baer and Maki [ | AH Plus™ | Amoxicillin at 10% w/w | DCT Optical density (spectrophotometer) | Not tested |
No significant difference at 1 day, 3 days or 7 days after mixing. Amoxicillin: improved antibacterial effect ( |
| Weckwerth et al. [ | AH Plus™, Sealer 26™ | Ketoconazole; Fluconazole at 0.5% w/w | ADT | Setting time, flowability |
Antifungal effect ( Setting time: not changed significantly. Flow: not changed significantly compared with pure sealers. All results: within ANSI/ADA specification No. 57. |
| Del Carpio-Perochena et al. [ | ThermaSeal Plus™ | Chitosan nanoparticles (CNps) | CFU calculation (log CFU/mL); Direct contact and membrane-restricted antibacterial experiments; CLSM, Sealer–dentine interface after pretreatment of dentine with CMCS (carboxymethyl-chitosan) or CMCS+RB (rose bengal) | Not tested |
CNps improved antibacterial properties significantly. After 1 week: antimicrobial activity was higher regardless of CNPs presence. After 4 weeks: bacterial colonization was higher. Chitosan group: significant reduction in total and viable biovolume. |
| Vilela Teixeira et al. [ | AH Plus™, Sealer 26™ | Nanostructured silver vanadate (AgVO3) decorated with silver nanoparticles at 0% w/w, 2.5% w/w, 5% w/w, 10% w/w | MIC (for AgVO3) by the visual assessment of turbidity; ADT | Flow, radiopacity |
MIC: 500 μg/mL for 0% = 2.5% = 5% = 10% inhibition zones, 0% = 2.5% = 5% no inhibition; 10% inhibition zones. 0% = 2.5% = 5% no inhibition, 10% inhibition zones. Flow: AH Plus™-decreased; Sealer 26™ not changed. Radiopacity: all values > 3 mm Al (within ANSI/ADA No. 57). |
| Vilela Teixeira et al. [ | AH Plus™, Sealer 26™ | Nanostructured silver vanadate (AgVO3) decorated with silver nanoparticles at 0%, 2.5%, 5%, 10% w/w | Not tested | Radiopacity, colour change |
Radiopacity: all values > 3 mm Al (within ANSI/ADA No. 57). Most significant discolouration of teeth at 180 days. Biggest change: AH Plus™ 2.5% and 10%; Sealer 26™ 10%. |
| Vilela Teixeira et al. [ | AH Plus™, Sealer 26™ | Nanostructured silver vanadate (AgVO3) decorated with silver nanoparticles at 0%, 2.5%, 5%, 10% w/w | DCT CFU counts; Epifluorescence microscopy | pH, solubility |
Fresh sealers: both pure and modified AH Plus™ and Sealer 26™ provided total inhibition of Set sealers: modified AH Plus™ showed no difference with pure AH Plus™ in all concentrations tested in DCT. Sealer 26™ 5% and 10% groups provided significantly higher inhibition of Epifluorescence images in set sealers showed more viable bacteria in nanomaterial-free groups. Solubility values of modified AH Plus™ and Sealer 26™ did not change significantly. pH: AH Plus™—significant difference in pH with time (6 h, 24 h, 14 days) of the modified groups compared with pure AH Plus™ except time points of 7 days and 30 days. Within the same concentration of AgVO3: pH varied at the initial time point and final time point of 30 days. All groups showed acidic pH in relation to the initial pH. pH: Sealer 26™—small pH variation between groups, except 10% group presenting a difference at 6 h, and 5% group presenting a difference at 7 days. Within the same concentration: increase of pH with time—significant difference at 6 h compared with 7 days, 14 days and 30 days. |
| Gong et al. [ | AH Plus™ | QAES (quaternary ammonium epoxy silicate) particles at 2%, 4%, 8% w/w | DCT; Optical density (spectrophotometer); Viability analysis of biofilm: CLSM | Not tested |
Inhibition of CLSM: |
| Kesler Shvero et al. [ | AH Plus™ | QPEI nanoparticles at 0.5%, 1%, 2% w/w | DCT Optical density (spectrophotometer); ADT; SEM | Not tested |
After 4 weeks of ageing: total bacterial growth inhibition in 2% group. DCT: total growth inhibition of up to 6 logs in viable counts in AH Plus + QPEI 2%. 0.5% and 1% of QPEI: 5 logs decrease in count. Significant differences between pure sealer and modified sealers. ADT: no effect—IABN (QPEI NPs) not diffusing into the agar. SEM: bacterial cell wall damage and lysis. |
| Kesler Shvero et al. [ | AH Plus™ | QPEI Nanoparticles at 2% w/w | Optical density (spectrophotometer); CLSM; Flow cytometry | Not tested |
Changes in fluorescence from green to red: increasing membrane potential. Bacterial membrane destabilization and cell death. QPEI NPs: incorporated in the sealer’s surface without damaging its mechanical properties. |
| Beyth et al. [ | RCS (BJM)™ | QPEI Nanoparticles at 1.5% w/w | DCT; Optical density (spectrophotometer), CFU counts ADT; SEM | Solubility, flow, cytotoxicity |
Antibacterial effect of immobilized nanoparticles (QPEI Nps): the number of residual viable bacteria decreased 6 logs vs the number in RCS™ without nanoparticles. SEM: syncytium-like cells and bacterial lysis after contact between the bacteria and a surface with QPEI NPs. Contact of bacteria with pure sealer: early biofilm formation with intact membranes and dividing cells. ADT: no inhibition in all groups. Antibacterial effect of QPEI NPs in suspension: a decrease in viable counts; after 1 h: no viable bacteria. SEM: NPs close to Adequate physical properties are maintained. Non-cytotoxic. |
| Barros et al. [ | AH Plus™ | QPEI nanoparticles at 1% or 2% w/w | DCT, CFU counts | Setting time, flow, solubility, apparent porosity, dimensional change, wettability, zeta potential, compressive strength |
Total eradication of 1% or 2% QPEI: no increase in the antibacterial effect of AH Plus™ after ageing. 1% and 2% QPEI: no significant change in physicochemical properties of AH Plus™—setting time, flow, solubility, apparent porosity and dimensional change (within ISO 6876:2001). Compressive strength: no change. QPEI: improved hydrophilicity. Wettability (by contact angle measurement) of AH Plus™: higher in 1% and 2%, lower in pure AH Plus™. Zeta potential: surface charge increased in 2% QPEI group. |
| Zaltsman et al. [ | AH Plus™ | QPEI nanoparticles variants | DCT, Optical density (spectrophotometer) | Not tested |
2% QPEI: total inhibition of 1% QPEI: only a partial effect. 0.5% and 0% QPEI: no effect SEM of pure AH Plus™: normal cells, intact cell wall. SEM QPEI-NLS at 2% w/w: morphologic changes in the bacterial cell wall with only a few bacteria on the surface. |
| Abramovitz et al. [ | AH Plus™ | QPEI nanoparticles at 1% w/w | CLSM | Not tested |
Percentage of live cells in the dentinal tubules of pure AH Plus™: significantly higher compared with AH Plus™ + 1% QPEI. QPEI effect: significant reduction in live bacteria ( |
| Barros et al. [ | AH Plus™ | QPEI nanoparticles at 2% w/w | DCT, CFU counts; membrane-restricted test; Crystal-violet microtiter-plate assay CLSM (data not shown in the paper) | Not tested |
Both pure and modified AH Plus™: low optical density values—more bacterial inhibition. Only AH Plus™ + 2% QPEI: significantly lower values ( |
Key: DCT = direct contact test; CLSM = confocal laser scanning microscopy; ADT = agar diffusion test; CFU = colony forming units; TAP = triple antibiotic paste (minocycline:metronidazole:ciprofloxacin 1:1:1); TAM = triple antibiotic mixture (doxycycline:metronidazole:ciprofloxacin 1:1:1.25); MIC = minimum inhibitory concentration; SEM = scanning electron microscopy; QPEI = quaternary ammonium polyethylenimine; NPs = nanoparticles.